These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 15168086)
1. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Baxevanis CN; Papamichail M Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086 [TBL] [Abstract][Full Text] [Related]
2. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112 [TBL] [Abstract][Full Text] [Related]
3. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413 [TBL] [Abstract][Full Text] [Related]
4. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity. Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
6. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Eshhar Z; Waks T; Gross G; Schindler DG Proc Natl Acad Sci U S A; 1993 Jan; 90(2):720-4. PubMed ID: 8421711 [TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Suzuki M; Curran KJ; Cheung NK Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831 [TBL] [Abstract][Full Text] [Related]
9. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766 [TBL] [Abstract][Full Text] [Related]
10. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A; Pohl C; Reinhold U; Abken H Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789 [TBL] [Abstract][Full Text] [Related]
11. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!]. Riffard C; Teillaud JL Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800 [TBL] [Abstract][Full Text] [Related]
13. Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy. Ren-Heidenreich L; Lum LG Curr Gene Ther; 2001 Sep; 1(3):253-5. PubMed ID: 12109140 [TBL] [Abstract][Full Text] [Related]
14. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy. Zhuang X; Long EO Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285 [TBL] [Abstract][Full Text] [Related]
16. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597 [TBL] [Abstract][Full Text] [Related]
17. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related]
18. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188 [TBL] [Abstract][Full Text] [Related]
19. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Rossig C; Bollard CM; Nuchtern JG; Merchant DA; Brenner MK Int J Cancer; 2001 Oct; 94(2):228-36. PubMed ID: 11668503 [TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance and immunity by redirected B cell-specific cytolytic T lymphocytes. Nguyen P; Duthoit CT; Geiger TL Gene Ther; 2007 Dec; 14(24):1739-49. PubMed ID: 17928872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]